405 related articles for article (PubMed ID: 18537678)
1. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
3. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
4. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
5. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
6. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
9. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
10. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
11. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
12. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
13. Macrocyclic proteasome inhibitors.
Krahn D; Ottmann C; Kaiser M
Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland F
IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
[No Abstract] [Full Text] [Related]
17. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
18. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
Demarchi F; Brancolini C
Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Daniel KG; Kuhn DJ; Kazi A; Dou QP
Curr Cancer Drug Targets; 2005 Nov; 5(7):529-41. PubMed ID: 16305349
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]